Bicalutamide (Casodex®)

Common name: Bicalutamide
Brand name: Casodex®
 

What is Bicalutamide?

Bicalutamide is a non-steroidal anti-androgen used to treat advanced (metastatic) prostate cancer. It works by reducing the amount of testosterone in the body.  Bicalutamide may be given in combination with other hormonal therapies such as luteinizing hormone releasing hormone (LHRH) analogues or in the surgical removal of the testicles (castration).
 

How is Bicalutamide administered?

Bicalutamide is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received bicalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Constipation
  • Decreased libido
  • High blood pressure
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Loss of appetite
  • Nausea
  • Muscle weakness
  • Swelling of breasts
 

Is Bicalutamide covered in my province or territory?*

Bicalutamide is covered by all provincial/territorial drug programs.

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=22652
 
Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive